Lung Cancer Trial, Recruiting NCT05191485 Sponsor: Sichuan Cancer Hospital and Research Institute Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05191485
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial includes two types of participants — patients and healthcare/industry stakeholders. Different parts of the trial have slightly different requirements.

Patients (across various parts of the trial):

  • People aged 18 or older who have been diagnosed with a specific type of lung cancer called primary invasive adenocarcinoma, confirmed during surgery through a tissue sample analysis
  • Depending on which part of the trial a patient is being considered for, they may or may not have already made a decision about whether to have molecular testing (genetic testing related to their lung cancer) — the trial site can clarify which applies

Healthcare professionals and other stakeholders (such as surgeons, nurses, hospital administrators, insurance company staff, and molecular testing company staff):

  • People aged 18 or older who have at least 2 years of relevant work experience
  • Surgeons and molecular testing company staff who have previous experience discussing lung cancer molecular testing with patients
  • Nurses, hospital administrators, and insurance company staff who have a working understanding of how medical decisions are made
  • For one part of the trial, clinicians must also be willing to take part voluntarily

Who may not be able to join:

  • People who are unable to understand the content of the research

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Sichuan Cancer Hospital and Research Institute
Registry
ClinicalTrials.gov
Start date
22 February 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The DA_LCMT 3.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov